GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Assertio Holdings Inc (NAS:ASRT) » Definitions » Cyclically Adjusted Price-to-FCF

ASRT (Assertio Holdings) Cyclically Adjusted Price-to-FCF : (As of Dec. 15, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Assertio Holdings Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Assertio Holdings Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Assertio Holdings's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Assertio Holdings Cyclically Adjusted Price-to-FCF Chart

Assertio Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.04 0.64 1.15 1.71 0.41

Assertio Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.41 0.30 0.39 -

Competitive Comparison of Assertio Holdings's Cyclically Adjusted Price-to-FCF

For the Drug Manufacturers - Specialty & Generic subindustry, Assertio Holdings's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assertio Holdings's Cyclically Adjusted Price-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Assertio Holdings's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Assertio Holdings's Cyclically Adjusted Price-to-FCF falls into.



Assertio Holdings Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Assertio Holdings's Cyclically Adjusted FCF per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Assertio Holdings's adjusted Free Cash Flow per Share data for the three months ended in Sep. 2024 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0/133.0289*133.0289
=0.000

Current CPI (Sep. 2024) = 133.0289.

Assertio Holdings Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201412 0.172 99.070 0.231
201503 -0.190 99.621 -0.254
201506 2.586 100.684 3.417
201509 3.231 100.392 4.281
201512 2.706 99.792 3.607
201603 -1.059 100.470 -1.402
201606 1.735 101.688 2.270
201609 1.110 101.861 1.450
201612 2.655 101.863 3.467
201703 1.000 102.862 1.293
201706 1.412 103.349 1.817
201709 -0.207 104.136 -0.264
201712 1.721 104.011 2.201
201803 -1.318 105.290 -1.665
201806 0.764 106.317 0.956
201809 3.268 106.507 4.082
201812 0.888 105.998 1.114
201903 1.693 107.251 2.100
201906 1.297 108.070 1.597
201909 1.815 108.329 2.229
201912 0.391 108.420 0.480
202003 -1.235 108.902 -1.509
202006 -0.816 108.767 -0.998
202009 -0.483 109.815 -0.585
202012 -0.200 109.897 -0.242
202103 -0.110 111.754 -0.131
202106 0.022 114.631 0.026
202109 0.103 115.734 0.118
202112 0.092 117.630 0.104
202203 0.595 121.301 0.653
202206 0.303 125.017 0.322
202209 0.175 125.227 0.186
202212 0.397 125.222 0.422
202303 0.445 127.348 0.465
202306 0.265 128.729 0.274
202309 0.032 129.860 0.033
202312 0.060 129.419 0.062
202403 0.079 131.776 0.080
202406 0.078 132.554 0.078
202409 0.000 133.029 0.000

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Assertio Holdings  (NAS:ASRT) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Assertio Holdings Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Assertio Holdings's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Assertio Holdings Business Description

Traded in Other Exchanges
N/A
Address
100 South Saunders Road, Suite 300, Lake Forest, IL, USA, 60045
Assertio Holdings Inc is a pharmaceutical company. It is engaged in providing solutions to advance patient care in the areas of neurology, orphan and specialty medicines. The company markets three FDA-approved products for various neurological conditions including Gralise, tablets for the management of postherpetic neuralgia; CAMBIA, for acute treatment of migraine attacks with or without aura in adults of age or older; and Zipsor, liquid-filled capsules for relief of mild to moderate pain.
Executives
Heather L Mason director 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Jeff L Vacirca director 4747 EXECUTIVE DRIVE, SUITE 510, SAN DIEGO CA 92121
James L Tyree director 100 ABBOTT PARK ROAD, ABBOTT PARK IL 60064-6400
Daniel A. Peisert director, officer: President & CEO C/O ASSERTIO THERAPEUTICS, INC., 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Paul Schwichtenberg officer: SVP and CFO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Ajay Patel officer: SVP and CAO 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FOREST IL 60045
Sam Schlessinger officer: SVP, General Counsel 100 SOUTH SAUNDERS ROAD, SUITE 300, LAKE FORREST IL 60045
William Mckee director
Crg Partners Iii - Parallel Fund (a) L.p. 10 percent owner C/O CAPITAL ROYALTY L.P., 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Todd N Smith director, officer: Director, Pres & CEO 1033 SKOKIE BOULEVARD, SUITE 355, NORTHBROOK IL 60062
Mark Strobeck officer: EVP & Chief Operating Officer 460 EAST SWEDESFORD ROAD, SUITE 1050, WAYNE PA 19087
Crg Partners Iii L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Cr Group L.p. 10 percent owner 1000 MAIN STREET, SUITE 2500, HOUSTON TX 77002
Andrea Heslin Smiley director 600 LEE ROAD, SUITE 100, WAYNE PA 19087
Megan C. Timmins officer: SVP, Gen Csl & Sec 600 LEE ROAD, SUITE 100, WAYNE PA 19087